Skip to main content

Table 3 Number of patients with at least one adverse event (> 5%), according to intensity

From: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

  Masitinib treatment (n= 26) Placebo (n= 8)
  All Severe All Severe
At least one adverse event 17 (65%) 4 (15%) 3 (38%) 1 (13%)
Oedema - all 8 (31%)    
Diarrhoea 6 (23%)    
Rash - all 5 (19%) 2 (8%)   
Anorexia 4 (15%) 2 (8%)   
Nausea 4 (15%) 1 (4%)   
Vomiting 3 (12%)    
Asthenia 3 (12%) 1 (4%)   
Bronchitis 2 (8%)    
Weight decreased 2 (8%)   1 (13%)  
Transaminases increased 2 (8%) 1 (4%)   
Arthralgia 2 (8%)    
Depression 2 (8%)   1 (13%)  
Balance disorder    1 (13%) 1 (13%)